Genesis Therapeutics
PrivateLast Round
Series B
Extension
Nov 13, 2024
Est. Valuation
$144M
Total Funding Raised
$304.1M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Genesis Therapeutics is a biotechnology company that utilizes a proprietary AI platform, GEMS, to discover and develop novel small-molecule drugs for severe and debilitating diseases.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, ML Platforms, Medical AI
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Infrastructure
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Genesis Therapeutics Comparables
Compare Genesis Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Terray Therapeutics | 87% | |
| PostEra | 86% | |
| Chai Discovery | 86% | |
Genesis Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B Extension | Nov 13, 2024 | ||||
| Series B | Aug 21, 2023 | ||||
| Series A | Dec 2, 2020 | ||||
| Seed | Nov 21, 2019 |
Genesis Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Andreessen Horowitz | Series A, Series B, Seed |
| Fidelity Management & Research Company | Series B |
| JAZZ Venture Partners | Series A |
| Propagator Ventures | Series A |
| Open Field Capital | Series A |
| T. Rowe Price | Series B, Series A |
| Ulu Ventures | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 3, 2026
Open roles increased to 177, 104% of headcount.
- Nov 13, 2024
NVentures led the latest VC Round.
Genesis Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Genesis Therapeutics's valuation, stock price, and market status.